Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for Secondary Prophylaxis of CMV in High-Risk Kidney/Pancreas Transplant Recipients
NCT06407232Phase 3Recruiting
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2024
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of letermovir in cytomegalovirus infection (CMV), sponsored by University of Wisconsin–Madison. Started Aug 2024; status: recruiting.
02
Drugs
letermovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT06407232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06407232.